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1217-52 M&analysis of Antiarrhythmic Drugs for Conversion of 
Atrial Fibrillation and the Maintenance of Sinus Rhythm: 
Combining Efficacy and Adverse Effects 
Leonardo Tamariz, Robert McNamara, Eric Bass, Johns Hopkins University, Baltimore, 
MD 
Background: Atrial fibrillation (AF) is the most common arrhythmia encountered in clim- 
cal practice. The purpose of this analysis is to summarize the evidence on the efficacy 
and adverse effects of agents now available for treatment of atrial fibrillation. Methods: 
MEDLINE and the clinical trial database of the Cochrane Collaboration were searched 
from 1946 to August 2001 for all randomized clinical trials reporting on the efficacy and 
adverse effects of drugs used in the conversion of AF and the maintenance of sinus 
rhythm. We extracted data on study quality, baseline characteristics, conversion of AF, 
maintenance of sinus rhythm and adverse effects. A flxed or random effects model was 
used taking into consideration the heterogeneity of the studies. Results: We identified 36 
randomized clinical trials (RCTs) on conversion of AF and 18 RCTs on maintenance after 
conversion The aggregate odds ratio for conversion of AF, compared to a control treat- 
ment (placebo, digoxin, diltiazem or verapamil) was 30.7 for ibutilide (95% confidence 
interval (Cl) 10.9.86), 12.8 for dofetilide (Cl 5.1-31.8), 13.2 for flecainide (Cl 6.4.27.4), 
3.9 for propafenone (Cl 2.3-6.8), 3.2 for amiodarone (Cl 2.5~5.1), 2.9 for quinidine (Cl 
1.2-6.9) and 1.1 for sotalol (Cl 0.1-6.9). The odds ratio for maintenance of sinus rhythm, 
compared to a control treatment, was 6.5 for amiodarone (Cl 4.1-10.5), 3.0 for pro- 
pafenone (Cl 2.0-4.7), 3.5 for quinidine (Cl 1.4-8.6), 2.5 for sotalol (Cl 1.7.3.7), 4.3 for 
flecainide (Cl 1.3-14.1) and 2.9 for dlsopyramide (Cl 1.4-6.1). The most efficacious drugs 
were associated to the highest risk of adverse effects. For the conversion of AF ibutillde 
and dofetilide had a significant risk of ventricular arrhytmias and for the maintenance of 
sinus rhythm amiodarone had a siginificant risk of adverse effects, however these were 
mostly noncardiac. Conclusion: Strong evidence of efficacy exists for using Ibutilide, 
dofetllide, flecainide, propafenone or amiodarone for conversion of AF, and for using 
amiodarone, propafenone, quinidine or sotalol for maintenance of sinus rhythm. However 
the decision in selecting an antiarrhytmic drug should also be based on the potential risk 
of adverse effects. 
1217-53 The Impact of Implanting Cardioverter-Defibrillators in 
Patients Who Meet the Multicenter Automatic 
Defibrillator Implantation Trial-II Criteria on the Health 
Care System at a Tertiary Referral Center 
Sana M. Al-Khatib, Eric Peterson, James Jollis, Yun Li, Kevin Anstrom. Christopher 
O’Connor, Kerry Lee, Linda Shaw. Robert M. Califf, Duke University Medical Center, 
Durham, NC 
Background: The recently published Multicenter Automatic Defibrillator Implantation 
Trial-II (MADIT-II) showed that patients with history of myocardial infarction and EF of 
30% or less have a significant reduction in mortality when treated with an lmplantable 
cardioverter defibrillator (ICD). The purpose of this study is to determine the impact of 
implanting an ICD in patients who meet the MADIT-II criteria on the health care system at 
a tertiary referral center. 
Methods: We used the Duke Cardiovascular Disease Database that has systematically 
collected the in-hospital clinical experience and the long-term follow-up of all cardiology 
patients who undergo a cardiac catheterization at Duke Medical Center. Of the patients 
who underwent cardiac catheterization between 1986 and 2001, we determined the num- 
ber of patients who would qualify for an ICD based on the MADIT-II results. Extrapolating 
cost data from the Antiarrhythmic Versus Implantable Defibrillators and MADIT-I trials, 
we estimated the cost of ICD implants in these patients. We also estimated the man- 
power needed to implant an ICD in these patients. 
Results: From 1986 through 2001, 51,001 patients underwent at least one cardiac cath- 
eterization. Of these, 1392 (2.7%) met the MADIT-II inclusion criteria. The cost of 
implanting an ICD in these patients would be 44,000,OOO. The cost of Implanting the ICD 
in these patients and managing them over three years would be $141,000,000. At least 
seven full time electrophysiologists would be required to meet the need for additional ICD 
implants within the next year. 
Conclusions: Detailed consideration of our coronary disease population over 15 years 
suggests that the proportion of patients who meet the MADIT-II criteria is relatively small. 
Despite this small number, our data indicate that the implantation of additional ICD’s in 
our institution will have substantial implications regarding manpower and cost. 
1217-54 Clinical Impact of Hand-Carried Cardiac Ultrasound in 
the Medical Clinic Performed by Medical Residents 
Lori B. Croft, Daniel Jacoby, Ira Galin, Thomas McGinn. Martin E. Goldman, Mount Sinai 
Medical Center, New York, NY 
Backaround: Hand-carried cardiac ultrasound (HCU) can provide rapid, bedslde 
assessment of ventricular and valvular function have only been utilized by cardiologists 
or technologists. Proper use of these potential echo-stethoscopes would empower all 
physicians to perform a point of care (POC) brief, diagnosis focused echocardiogram 
(echo) to improve bedside cardiac assessment to complement their physical exam. 
Obiective: To determine (I) whether medical residents with brief echo training can effec- 
tively acquire and interpret HCU POC echo’s and (2) to determine the impact of these 
echo’s on patient (pt) care in their outpatient clinic practice. 
Methods: First and second year medlcal residents underwent a 2 l/2 day hands-on tuto- 
rial to perform and interpret a POC echo using the Phillips Optigo@ (Andover, MA) HES. 
The echo consisted of four views (parasternal long and short, apical four and two cham- 
ber) to define left and right ventricular function and pericardial effusions. Color Doppler 
interrogated for significant valvular abnormalities. No pulsed or continuous wave Doppler 
or M-mode was used. The echo’s were overread and repeated by an echocardtologist 
who evaluated the residents’ technical and interpretive skills. 
Results: Residents performed 53 echo’s in the outpatient clinic as part of their routme pt 
evaluation. The mean time for their echo was 4.32 1.2 minutes. The residents performed 
technically diagnostic echo’s in 94% and interpreted their studies correctly in 89% of pts. 
Residents missed 6 major echo findings. Residents reported their echo reinforced or 
changed their pre-echo diagnosis in 76% of the cases and induced a change in manage- 
ment in 38%. 
Conclusions: This pilot study demonstrated that It IS feasible to train medical residents 
to perform, interpret and integrate a rapid HCU POC echo after a short training period. 
Residents’ echo’s had a sigmficant impact on their pt care. Implications of this study sup- 
port formally educating medical residents to utilize a bedside echo-stethoscope as part of 
their routme pt cars. 
1217-55 Development of a Clinical Quality Care Index Predicts 
Hospital Readmission for Heart Failure 
Ricardo Vicuna, Andrew J. Krainik, Jun Chiong, Stephanie H. Dunla9 University of 
Illinois at Chicago, Chicago, IL 
Background: Despite therapeutic advances in heart failure (HF). readmission rates 
remain high and under use of ACE inhibitors (ACEI) in HF patients (pts) at hospital dls- 
charge is prevalent. Multiple quality care indicators for assessing in-hospital care of HF 
pts. have been published. From the literature, 9 clinical indicators were chosen and com- 
bined into a Quality Care Instrument (QCI) for assessing in-hospital care of HF pts. The 
purpose of this study was to investigate the association between the QCI score and risk 
for HF readmission. 
Methods: All in-pt. medical records from our institution with a pnmary discharge diagno- 
sis of HF occurring during fiscal year 1996 were retrospectively examined and assessed 
for readmiswn through 1998. The 9 clinical indicators were: assessment of LV function; 
ACEI therapy (tx); target ACEI dose; multiple weight measurements; hydralazine-nitrate 
tx if ACEI contraindicated; increased diuretic tx from admiswn; digoxin tx; aspirin tx in 
ischemic pts; sodium/fluid restriction and/or dietary consult. Drug tx was not scored if 
there were contraindications to the drug being evaluated. The overall QCI was calculated 
as [number of indicators present c number of applicable indicators]. Cox proportional 
hazards models were constructed using the QCI as a predictor for readmission, control- 
ling for demographic and clinical variables. 
Results: The study was comprised of 223 pts (53% female, 65% black, 19% Hispanic, 
14% white) with mean age of 60 + 15.3 yrs(SD). QCI scores ranged from O-l, with a 
median of 0.75. 84 pts. (38%) were readmitted at least once during 2 yr. follow-up. Read- 
mission rates at 30, 90, 180, and 365 days were 6%, 15%, 22%, and 30%, respectively. 
Records with a QCI score in the lowest quartile (<0.60), were at highest risk for HF read- 
mission (RR = 2.06, p=O.Ol) and for all other cardiovascular causes (RR=l.66, p=O.O2). 
Conclusion: Use of the Quality Care Instrument was predictive for readmlssion for both 
HF and all cardiovascular causes. The analysis suggests that implementation of the 9 
Indicators in the QCI during HF hospitalizabons may limit future hospitalizations for both 
HF and all cardiovascular causes. 
1217-56 Time Course of Morbidity and Mortality After a 
Myocardial Infarction Complicated by Lefl Ventricular 
Systolic Dysfunction or Heart Failure 
J. G. Cleland, J. Kjekshus, K. Dickstein, S. Om, M. Rome, University of Hull, Kingston 
upon Hull, United Kingdom 
Background: Patients with major left ventricular systolic dysfunction (LVSD) or heart 
failure after a myocardial infarction (Ml) have a poor prognosis, but the time course of 
morbidity and mortality are poorly described in patients receiving contemporary therapy. 
Aims: To describe the time course of stroke, Ml and death in patients who have survived 
an Ml complicated by LVSD or hearl failure. Methods: 5477 patients with MI with evi- 
dence suggesting major cardiac damage were enrolled in the OPTIMAAL trial and fol- 
lowed for a mean of 2.7 years. Events, including death, resuscitated cardiac arrest 
(RCA), MI and stroke, were independently adjudicated. Results: The mean age was 
67.4 years. At study end, 4038 events had been evaluated including 946 deaths, 988 
Ml’s, and 300 strokes. The distribution of events in relation to time from randomization is 
shown in the table. 
Events and (Cumulative % of all Events Adjudicated ) 
Death (N=946) RCA (N=l30) Ml (N=988) Stroke (N=300) 
O-30 days 235 (24.8%) 52 (40.0%) 252 (25.5%) 67 (22.3%) 
30.180 days 202 (46.2%) 28 (61.5%) 270 (52.6%) 34 (33.6%) 
180.365 days 148 (61.8%) 16 (73.8%) 147 (67.7%) 51 (50.6%) 
>365 361 (100%) 34 (100%) 319 (100%) 148 (100%) 
Conclusions: There is a high initial and then a rapid decline in mortality and, to a lesser 
extent, other events after myocardial infarction complicated by LVSD or hearl failure. 
